Analyst Price Targets — BIOA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 27, 2026 8:18 am | Adam Walsh | Roth Capital | $36.00 | $16.20 | TheFly | BioAge Labs initiated with a Buy at Roth Capital |
| May 13, 2026 9:54 am | — | BTIG | $40.00 | $18.19 | TheFly | BioAge Labs initiated with a Buy at BTIG |
| March 27, 2026 10:21 am | — | Needham | $50.00 | $16.15 | TheFly | BioAge Labs initiated with a Buy at Needham |
| February 18, 2026 11:08 am | Roger Song | Jefferies | $62.00 | $19.63 | TheFly | BioAge Labs upgraded to Buy from Hold at Jefferies |
| February 4, 2026 1:30 pm | — | Morgan Stanley | $23.00 | $19.99 | TheFly | BioAge Labs price target raised to $23 from $12 at Morgan Stanley |
| December 5, 2025 6:29 pm | — | Morgan Stanley | $12.00 | $11.40 | TheFly | BioAge Labs upgraded to Equal Weight from Underweight at Morgan Stanley |
| March 7, 2025 1:24 pm | — | Morgan Stanley | $5.00 | $4.55 | TheFly | BioAge Labs assumed with an Underweight at Morgan Stanley |
| December 9, 2024 8:00 am | Roger Song | Jefferies | $7.00 | $4.65 | StreetInsider | Jefferies Downgrades BioAge Labs Inc (BIOA) to Hold |
| October 21, 2024 7:32 am | Samantha Semenkow | Citigroup | $45.00 | $23.86 | TheFly | BioAge Labs initiated with a Buy at Citi |
| October 21, 2024 3:37 am | Roger Song | Jefferies | $42.00 | $23.86 | StreetInsider | Jefferies Starts BioAge Labs Inc (BIOA) at Buy |
Latest News for BIOA
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3 Trial builds on previously reported Phase 1 results in which…
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company's plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BIOA.
U.S. House Trading
No House trades found for BIOA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.